

Thierry Burnouf

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2637650/thierry-burnouf-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244
papers

6,992
citations

43
h-index

72
g-index

271
ext. papers

8,147
ext. citations

5
avg, IF

6.41
L-index

#	Paper	IF	Citations
244	Regenerative effect of expired platelet concentrates in human therapy: An update.. <i>Transfusion and Apheresis Science</i> , 2022 , 103363	2.4	1
243	Near-infrared-driven photoablation of lung cancer tumors utilizing biomimetic platelet-polyethyleneimine-polypyrrole drug-free nanoparticles. <i>Materials and Design</i> , 2022 , 215, 110481	8.1	1
242	COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.. <i>Clinical Microbiology Reviews</i> , 2022 , e0020021	34	3
241	Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma.. <i>European Journal of Cancer</i> , 2022 , 166, 208-218	7.5	2
240	Platelet and extracellular vesicles in COVID-19 infection and its vaccines. <i>Transfusion and Apheresis Science</i> , 2022 , 103459	2.4	0
239	Whole and fractionated human platelet lysate biomaterials-based biotherapy induces strong neuroprotection in experimental models of amyotrophic lateral sclerosis.. <i>Biomaterials</i> , 2021 , 280, 121311	15.6	1
238	Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine. <i>ACS Biomaterials Science and Engineering</i> , 2021 ,	5.5	1
237	Ex Vivo Expanded Circulating Tumor Cells for Clinical Anti-Cancer Drug Prediction in Patients with Head and Neck Cancer. <i>Cancers</i> , 2021 , 13,	6.6	4
236	Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. <i>Vox Sanguinis</i> , 2021 , 116, 872-879	3.1	1
235	International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary. <i>Vox Sanguinis</i> , 2021 , 116, 1117-1135	3.1	0
234	International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses. <i>Vox Sanguinis</i> , 2021 , 116, e71-e120	3.1	1
233	Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment. <i>Brain</i> , 2021 , 144, 3142-3158	11.2	3
232	Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety. <i>Vox Sanguinis</i> , 2021 , 116, 13-14	3.1	14
231	Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries. <i>Vox Sanguinis</i> , 2021 , 116, 18-35	3.1	27
230	Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation. <i>Platelets</i> , 2021 , 32, 226-237	3.6	7
229	Prospective Therapeutic Applications of Platelet Extracellular Vesicles. <i>Trends in Biotechnology</i> , 2021 , 39, 598-612	15.1	24
228	Human platelet lysates for human cell propagation. <i>Platelets</i> , 2021 , 32, 152-162	3.6	6

227	Extensive characterization of the composition and functional activities of five preparations of human platelet lysates for dedicated clinical uses. <i>Platelets</i> , 2021 , 32, 259-272	3.6	6
226	Iridium Oxide Nanoparticle-Protein Corona Neural Interfaces with Enhanced Electroactivity and Bioactivity Enable Electrically Manipulatable Physical and Chemical Neuronal Activation. <i>Advanced Materials Interfaces</i> , 2021 , 8, 2100694	4.6	1
225	COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. <i>Viruses</i> , 2021 , 13,	6.2	10
224	Removal of minute virus of mice-mock virus particles by nanofiltration of culture growth medium supplemented with 10% human platelet lysate. <i>Cytotherapy</i> , 2021 , 23, 902-907	4.8	2
223	A purified human platelet pellet lysate rich in neurotrophic factors and antioxidants repairs and protects corneal endothelial cells from oxidative stress. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 142, 112046	7.5	4
222	Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity. <i>Blood Transfusion</i> , 2021 , 19, 467-478	3.6	0
221	Points to consider in the preparation and transfusion of COVID-19 convalescent plasma in low and middle-income countries 2020 , 22, 5-7		4
220	Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections. <i>Npj Vaccines</i> , 2020 , 5, 103	9.5	2
219	Nanofiltration of growth media supplemented with human platelet lysates for pathogen-safe xeno-free expansion of mesenchymal stromal cells. <i>Cytotherapy</i> , 2020 , 22, 458-472	4.8	7
218	Intelligent micro-/nanorobots as drug and cell carrier devices for biomedical therapeutic advancement: Promising development opportunities and translational challenges. <i>Biomaterials</i> , 2020 , 260, 120163	15.6	27
217	Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop. <i>Journal of Biomedical Science</i> , 2020 , 27, 45	13.3	14
216	Biological and Rheological Properties of a Virally Inactivated Fibrin Glue (Biocol [®]): Comparison to an Autologous Fibrin Glue 2020 , 71-78		
215	The Role of Nanofiltration in the Pathogen Safety of Biologicals: An Update. <i>Current Nanoscience</i> , 2020 , 16, 413-424	1.4	5
214	Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA). <i>Transfusion and Apheresis Science</i> , 2020 , 59, 102717	2.4	11
213	Plasma fractionation in countries with limited infrastructure and low-/medium income: How to move forward?. <i>Transfusion and Apheresis Science</i> , 2020 , 59, 102715	2.4	4
212	Effect of cell culture biomaterials for completely xeno-free generation of human induced pluripotent stem cells. <i>Biomaterials</i> , 2020 , 230, 119638	15.6	15
211	Recovered plasma for fractionation: call for quality standards to end wastage. <i>Vox Sanguinis</i> , 2020 , 115, 213-214	3.1	2
210	Ex Vivo Expansion and Drug Sensitivity Profiling of Circulating Tumor Cells from Patients with Small Cell Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9

209	Production and Quality Requirements of Human Platelet Lysate: A Position Statement from the Working Party on Cellular Therapies of the International Society of Blood Transfusion. <i>Trends in Biotechnology</i> , 2020 , 38, 13-23	15.1	42
208	Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. <i>Vox Sanguinis</i> , 2020 , 115, 485-487	3.1	55
207	Chemoradiotherapy for Inoperable Carotid Body Leiomyosarcoma: A Case Report and Review of Literature. <i>Frontiers in Oncology</i> , 2020 , 10, 599403	5.3	
206	The effect of human platelet lysate on the differentiation ability of human adipose-derived stem cells cultured on ECM-coated surfaces. <i>Journal of Materials Chemistry B</i> , 2019 , 7, 7110-7119	7.3	10
205	Improving haemophilia therapy in developing countries: virus-safe cryoprecipitate. <i>Vox Sanguinis</i> , 2019 , 114, 635-636	3.1	2
204	New monoclonal/bi-specific antibodies: Reshaping transfusion medicine beyond replacement. <i>Transfusion and Apheresis Science</i> , 2019 , 58, 208-211	2.4	3
203	A double-virally-inactivated (Intercept-solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells. <i>Transfusion</i> , 2019 , 59, 2061-2073	2.9	9
202	NanoBioAnalytical characterization of extracellular vesicles in 75-nm nanofiltered human plasma for transfusion: A tool to improve transfusion safety. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019 , 20, 101977	6	6
201	Nanoformulation properties, characterization, and behavior in complex biological matrices: Challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. <i>Advanced Drug Delivery Reviews</i> , 2019 , 148, 146-180	18.5	45
200	Human platelet lysate current standards and future developments. <i>Transfusion</i> , 2019 , 59, 1407-1413	2.9	38
199	Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates. <i>Frontiers in Neurology</i> , 2019 , 10, 835	4.1	28
198	A bioinspired hyperthermic macrophage-based polypyrrole-polyethylenimine (Ppy-PEI) nanocomplex carrier to prevent and disrupt thrombotic fibrin clots. <i>Acta Biomaterialia</i> , 2019 , 96, 468-479	10.8	17
197	Blood products: unmet needs for essential medicines. <i>Lancet Haematology</i> , 2019 , 6, e598-e599	14.6	7
196	The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. <i>Journal of Biomedical Science</i> , 2019 , 26, 89	13.3	11
195	Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past. <i>Transfusion and Apheresis Science</i> , 2019 , 58, 102674	2.4	13
194	Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation. <i>International Journal of Nanomedicine</i> , 2019 , 14, 8847-8859	7.3	35
193	Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cells. <i>New Biotechnology</i> , 2019 , 49, 151-160	6.4	12
192	Extracellular Microvesicles as New Industrial Therapeutic Frontiers. <i>Trends in Biotechnology</i> , 2019 , 37, 707-729	15.1	84

191	What can be learned in the snake antivenom field from the developments in human plasma derived products?. <i>Toxicon</i> , 2018 , 146, 77-86	2.8	0
190	Multifaceted regenerative lives of expired platelets. <i>ISBT Science Series</i> , 2018 , 13, 323-330	1.1	1
189	Prophylactic supplement with melatonin successfully suppresses the pathogenesis of periodontitis through normalizing RANKL/OPG ratio and depressing the TLR4/MyD88 signaling pathway. <i>Journal of Pineal Research</i> , 2018 , 64, e12464	10.4	34
188	International Forum on GMP-grade human platelet lysate for cell propagation: summary. <i>Vox Sanguinis</i> , 2018 , 113, 80-87	3.1	30
187	International Forum on GMP-grade human platelet lysate for cell propagation. <i>Vox Sanguinis</i> , 2018 , 113, e1-e25	3.1	8
186	Circulatory-cell-mediated nanotherapeutic approaches in disease targeting. <i>Drug Discovery Today</i> , 2018 , 23, 934-943	8.8	19
185	Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products. <i>Frontiers in Medicine</i> , 2018 , 5, 33	4.9	34
184	Bitter progress in the treatment of haemophilia A in low-income countries. <i>Lancet Haematology</i> , 2018 , 5, e239	14.6	5
183	The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 1895-1900	15.4	69
182	A Gelatin Hydrogel-Containing Nano-Organic PEI/Ppy with a Photothermal Responsive Effect for Tissue Engineering Applications. <i>Molecules</i> , 2018 , 23,	4.8	36
181	Fabrication of co-electrodeposition of plasma proteins/iridium oxide hybrid films. <i>Ceramics International</i> , 2018 , 44, S117-S120	5.1	2
180	An overview of plasma fractionation. <i>Annals of Blood</i> , 2018 , 3, 33-33	0.6	11
179	Role of the mini-pool cryoprecipitate technology for cost-saving and guarantee of local Factor VIII, Von Willebrand Factor and Fibrinogen product supply: Egypt experience. <i>Annals of Blood</i> , 2018 , 3, 22-22	0.6	3
178	Blood transfusion in sub-Saharan Africa: understanding the missing gap and responding to present and future challenges. <i>Vox Sanguinis</i> , 2018 , 113, 726-736	3.1	19
177	Platelet concentrate supernatants alter endothelial cell mRNA and protein expression patterns as a function of storage length. <i>Transfusion</i> , 2018 , 58, 2635-2644	2.9	2
176	Principles of haemophilia care: The Asia-Pacific perspective. <i>Haemophilia</i> , 2018 , 24, e245-e246	3.3	1
175	Self-Targeting, Immune Transparent Plasma Protein Coated Nanocomplex for Noninvasive Photothermal Anticancer Therapy. <i>Advanced Healthcare Materials</i> , 2017 , 6, 1700181	10.1	29
174	Red blood cell transfusion and outcome in cancer. <i>Transfusion and Apheresis Science</i> , 2017 , 56, 287-290	2.4	9

173	Platelet transfusion in thrombocytopenic cancer patients: Sometimes justified but likely insidious. <i>Transfusion and Apheresis Science</i> , 2017 , 56, 305-309	2.4	3
172	Transfusion-related immunomodulation and cancer. <i>Transfusion and Apheresis Science</i> , 2017 , 56, 336-340	2.4	43
171	Convalescent Plasma and the Dose of Ebola Virus Antibodies. <i>New England Journal of Medicine</i> , 2017 , 376, 1296-7	59.2	5
170	Catalase-Modulated Heterogeneous Fenton Reaction for Selective Cancer Cell Eradication: SnFeO Nanocrystals as an Effective Reagent for Treating Lung Cancer Cells. <i>ACS Applied Materials & Interfaces</i> , 2017 , 9, 1273-1279	9.5	50
169	Current methods to manufacture human platelet lysates for cell therapy and tissue engineering: possible trends in product safety and standardization. <i>ISBT Science Series</i> , 2017 , 12, 168-175	1.1	3
168	The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017 , 11, 3236-3240	4.4	23
167	Comparison of three human platelet lysates used as supplements for in vitro expansion of corneal endothelium cells. <i>Transfusion and Apheresis Science</i> , 2017 , 56, 769-773	2.4	16
166	Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease. <i>Biomaterials</i> , 2017 , 142, 77-89	15.6	24
165	Reflections on multiple strategies to reduce transfusion in cancer patients: A joint narrative. <i>Transfusion and Apheresis Science</i> , 2017 , 56, 322-329	2.4	3
164	The microbiome and transfusion in cancer patients. <i>Transfusion and Apheresis Science</i> , 2017 , 56, 330-335	2.4	6
163	The Current Global Status and Production Trends of Plasma Fractionation. <i>The Korean Journal of Blood Transfusion</i> , 2017 , 28, 113-125	0.3	1
162	Duration of red blood cell storage and inflammatory marker generation. <i>Blood Transfusion</i> , 2017 , 15, 145-152	3.6	22
161	Towards pathogen inactivation of red blood cells and whole blood targeting viral DNA/RNA: design, technologies, and future prospects for developing countries. <i>Blood Transfusion</i> , 2017 , 15, 512-521	3.6	42
160	Single-use technology for solvent/detergent virus inactivation of industrial plasma products. <i>Transfusion</i> , 2016 , 56, 1384-93	2.9	7
159	Convalescent Ebola plasma: assessing neutralizing antibodies at the right stage. <i>Vox Sanguinis</i> , 2016 , 111, 456-457	3.1	1
158	Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion. <i>Journal of Thrombosis and Haemostasis</i> , 2016 , 14, 2073-2074	15.4	1
157	Current status and new developments in the production of plasma derivatives. <i>ISBT Science Series</i> , 2016 , 11, 18-25	1.1	4
156	Impact of Transfusion on Cancer Growth and Outcome. <i>Cancer Growth and Metastasis</i> , 2016 , 9, 1-8		35

155	Convalescent Plasma for Ebola Virus Disease. <i>New England Journal of Medicine</i> , 2016 , 374, 2500	59.2	14
154	Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion. <i>Cytotherapy</i> , 2016 , 18, 911-24	4.8	9
153	Quality, safety and sustained therapeutic efficacy of blood-derived serum eye drops to treat dry eye syndrome: R&D road map for future progress. <i>Transfusion and Apheresis Science</i> , 2016 , 54, 168-9	2.4	7
152	Commentary on technical specifications and safety requirements of serum eye drops: Keeping a close eye on the content in cytokines. <i>Transfusion and Apheresis Science</i> , 2016 , 54, 170-1	2.4	1
151	Activity-based and fraction-guided analysis of <i>Phyllanthus urinaria</i> identifies loliolide as a potent inhibitor of hepatitis C virus entry. <i>Antiviral Research</i> , 2016 , 130, 58-68	10.8	38
150	Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?. <i>Biomaterials</i> , 2016 , 76, 371-87	15.6	279
149	Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome. <i>PLoS ONE</i> , 2016 , 11, e0153573	3.7	11
148	Anti-Human Platelet Antigen-1a Immunoglobulin G Preparation Intended to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia. <i>PLoS ONE</i> , 2016 , 11, e0162973	3.7	5
147	Plasma for fractionation: looking at its safety from a comprehensive angle. <i>Transfusion</i> , 2016 , 56, 2900-2901	2.4	1
146	Smart blood cell and microvesicle-based Trojan horse drug delivery: Merging expertise in blood transfusion and biomedical engineering in the field of nanomedicine. <i>Transfusion and Apheresis Science</i> , 2016 , 54, 309-18	2.4	30
145	Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries. <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0003501	4.8	22
144	Removal of transmissible spongiform encephalopathy prion from large volumes of cell culture media supplemented with fetal bovine serum by using hollow fiber anion-exchange membrane chromatography. <i>PLoS ONE</i> , 2015 , 10, e0122300	3.7	12
143	Anti-inflammatory effects of platelet biomaterials in a macrophage cellular model. <i>Vox Sanguinis</i> , 2015 , 109, 138-47	3.1	23
142	Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro. <i>Transfusion and Apheresis Science</i> , 2015 , 53, 246-52	2.4	15
141	The role of microparticles in inflammation and transfusion: A concise review. <i>Transfusion and Apheresis Science</i> , 2015 , 53, 159-67	2.4	55
140	Human plasma-derived immunoglobulin G fractionated by an aqueous two-phase system, caprylic acid precipitation, and membrane chromatography has a high purity level and is free of detectable in vitro thrombogenic activity. <i>Vox Sanguinis</i> , 2015 , 108, 169-77	3.1	10
139	Platelet microparticles and cancer: An intimate cross-talk. <i>Transfusion and Apheresis Science</i> , 2015 , 53, 168-72	2.4	51
138	Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion. <i>New Biotechnology</i> , 2015 , 32, 199-211	6.4	111

137	Nanofiltration to remove microparticles and decrease the thrombogenicity of plasma: in vitro feasibility assessment. <i>Transfusion</i> , 2015 , 55, 2433-44	2.9	25
136	TnBP Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus. <i>PLoS ONE</i> , 2015 , 10, e0117800	3.7	8
135	A Call for Incorporating Social Research in the Global Struggle against Snakebite. <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0003960	4.8	24
134	Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believing. <i>Transfusion and Apheresis Science</i> , 2015 , 53, 95-8	2.4	13
133	An overview of the role of microparticles/microvesicles in blood components: Are they clinically beneficial or harmful?. <i>Transfusion and Apheresis Science</i> , 2015 , 53, 137-45	2.4	82
132	Platelet microparticle: a sensitive physiological "fine tuning" balancing factor in health and disease. <i>Transfusion and Apheresis Science</i> , 2015 , 52, 12-8	2.4	47
131	Ebola virus convalescent blood products: where we are now and where we may need to go. <i>Transfusion and Apheresis Science</i> , 2014 , 51, 120-5	2.4	47
130	Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. <i>Biologicals</i> , 2014 , 42, 260-70	1.8	18
129	Ebola: a call for blood transfusion strategy in sub-Saharan Africa. <i>Lancet, The</i> , 2014 , 384, 1347-8	4.0	27
128	No no Go in plasma fractionation in the world's emerging economies: still a question asked 70 years after the COHN process was developed!. <i>Transfusion and Apheresis Science</i> , 2014 , 51, 113-9	2.4	10
127	Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. <i>Blood Reviews</i> , 2014 , 28, 155-66	11.1	132
126	Multifaceted regenerative lives of expired platelets in the second decade of the 21st century. <i>Transfusion and Apheresis Science</i> , 2014 , 51, 107-12	2.4	14
125	Standardized human platelet lysate supplement demonstrates to be an effective, serum-free, xeno-free, FBS replacement for culturing AT-/BM-/and UC-mesenchymal stem cells. <i>Cytotherapy</i> , 2014 , 16, S85	4.8	4
124	Platelets effects on tumor growth. <i>Seminars in Oncology</i> , 2014 , 41, 359-69	5.5	78
123	Regulation of tumor growth and metastasis: the role of tumor microenvironment. <i>Cancer Growth and Metastasis</i> , 2014 , 7, 9-18		125
122	A multicomponent strategy to improve the availability of antivenom for treating snakebite envenoming. <i>Bulletin of the World Health Organization</i> , 2014 , 92, 526-32	8.2	42
121	Platelet-cancer interactions. <i>Seminars in Thrombosis and Hemostasis</i> , 2014 , 40, 296-305	5.3	100
120	An approach to outreach patients with von Willebrand disease in Egypt by targeting women with heavy menstrual bleeding and/or bleeding symptoms. <i>Haemophilia</i> , 2014 , 20, 238-43	3.3	4

119	New approaches for manufacturing plasma derivatives. <i>ISBT Science Series</i> , 2014 , 9, 160-167	1.1	7
118	Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG. <i>Transfusion</i> , 2014 , 54, 169-78	2.9	13
117	Ex vivo expansion of bovine corneal endothelial cells in xeno-free medium supplemented with platelet releasate. <i>PLoS ONE</i> , 2014 , 9, e99145	3.7	20
116	Dengue virus inactivation by minipool TnBP/Triton X-45 treatment of plasma and cryoprecipitate. <i>Vox Sanguinis</i> , 2013 , 104, 1-6	3.1	13
115	Antimicrobial activity of platelet (PLT)-poor plasma, PLT-rich plasma, PLT gel, and solvent/detergent-treated PLT lysate biomaterials against wound bacteria. <i>Transfusion</i> , 2013 , 53, 138-46	2.9	87
114	The platelet-cancer loop. <i>European Journal of Internal Medicine</i> , 2013 , 24, 393-400	3.9	113
113	Platelet gels. <i>ISBT Science Series</i> , 2013 , 8, 131-136	1.1	3
112	Virally inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model. <i>Transfusion</i> , 2013 , 53, 1918-28	2.9	16
111	Blood-derived biomaterials and platelet growth factors in regenerative medicine. <i>Blood Reviews</i> , 2013 , 27, 77-89	11.1	143
110	Treatment of nonhealing diabetic lower extremity ulcers with skin graft and autologous platelet gel: a case series. <i>BioMed Research International</i> , 2013 , 2013, 837620	3	27
109	Human platelet antigen alleles in 998 Taiwanese blood donors determined by sequence-specific primer polymerase chain reaction. <i>BioMed Research International</i> , 2013 , 2013, 973789	3	8
108	Natural Scrub Typhus Antibody Suppresses HIV CXCR4(X4) Viruses. <i>Gastroenterology Insights</i> , 2013 , 5, e8	2.1	4
107	Single-donor allogeneic platelet fibrin glue and osteoconductive scaffold in orbital floor fracture reconstruction. <i>Annals of Plastic Surgery</i> , 2013 , 70, 370-4	1.7	9
106	Human blood-derived fibrin releasates: composition and use for the culture of cell lines and human primary cells. <i>Biologicals</i> , 2012 , 40, 21-30	1.8	29
105	Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation. <i>Biologicals</i> , 2012 , 40, 129-33	1.8	14
104	Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor. <i>Transfusion</i> , 2012 , 52, 1721-8	2.9	23
103	Plasma fractionation. <i>ISBT Science Series</i> , 2012 , 7, 62-67	1.1	1
102	Impact of solvent/detergent treatment of plasma on transfusion-relevant bacteria. <i>Vox Sanguinis</i> , 2012 , 102, 277-84	3.1	15

101	Purification of IgG and albumin from human plasma by aqueous two phase system fractionation. <i>Biotechnology Progress</i> , 2012 , 28, 1005-11	2.8	15
100	Recombinant plasma proteins. <i>Vox Sanguinis</i> , 2011 , 100, 68-83	3.1	32
99	A chromatographically purified human TGF- β fraction from virally inactivated platelet lysates. <i>Vox Sanguinis</i> , 2011 , 101, 215-20	3.1	13
98	Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII. <i>Haemophilia</i> , 2011 , 17, e884-8	3.3	11
97	Expansion of adipose tissue mesenchymal stromal progenitors in serum-free medium supplemented with virally inactivated allogeneic human platelet lysate. <i>Transfusion</i> , 2011 , 51, 770-8	2.9	66
96	Pathogen reduction technique for fresh-frozen plasma, cryoprecipitate, and plasma fraction minipools prepared in disposable processing bag systems. <i>Transfusion</i> , 2011 , 51, 446-7; author reply 447-8 ⁹	2.9	8
95	Plasma fractionation in Asia-Pacific: challenges and perspectives. <i>ISBT Science Series</i> , 2011 , 6, 366-372	1.1	3
94	Antivenoms for the treatment of snakebite envenomings: the road ahead. <i>Biologicals</i> , 2011 , 39, 129-42	1.8	102
93	A novel technique combining platelet gel, skin graft, and fibrin glue for healing recalcitrant lower extremity ulcers. <i>Dermatologic Surgery</i> , 2010 , 36, 453-60	1.7	54
92	Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. <i>Transfusion Medicine</i> , 2010 , 20, 48-61	1.3	46
91	Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. <i>Vox Sanguinis</i> , 2010 , 98, 12-28	3.1	114
90	A novel virally inactivated human platelet lysate preparation rich in TGF-beta, EGF and IGF, and depleted of PDGF and VEGF. <i>Biotechnology and Applied Biochemistry</i> , 2010 , 56, 151-60	2.8	12
89	Influence of ethanol on the release of growth factors in human blood-derived platelet gels. <i>Biologicals</i> , 2010 , 38, 120-7	1.8	13
88	A novel core fractionation process of human plasma by expanded bed adsorption chromatography. <i>Analytical Biochemistry</i> , 2010 , 399, 102-9	3.1	22
87	A virally inactivated platelet-derived growth factor/vascular endothelial growth factor concentrate fractionated from human platelets. <i>Transfusion</i> , 2010 , 50, 1702-11	2.9	12
86	Plasma fractionation issues. <i>Biologicals</i> , 2009 , 37, 88-93	1.8	31
85	Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom. <i>Biologicals</i> , 2009 , 37, 306-12	1.8	12
84	A virally inactivated functional growth factor preparation from human platelet concentrates. <i>Vox Sanguinis</i> , 2009 , 97, 119-28	3.1	34

83	New methods of plasma fractionation and presentation of the mini-pool fractionation procedure developed in Egypt. <i>ISBT Science Series</i> , 2009 , 4, 99-106	1.1	9
82	Blood-derived biomaterials: fibrin sealant, platelet gel and platelet fibrin glue. <i>ISBT Science Series</i> , 2009 , 4, 136-142	1.1	23
81	Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR HyperD and C18 sorbents. <i>Analytical Biochemistry</i> , 2009 , 389, 69-73	3.1	5
80	In vitro release of growth factors from platelet-rich fibrin (PRF): a proposal to optimize the clinical applications of PRF. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2009 , 108, 56-61		101
79	Quality of plasma and its fractionation. <i>ISBT Science Series</i> , 2008 , 3, 148-151	1.1	1
78	Solvent/detergent treatment of platelet concentrates enhances the release of growth factors. <i>Transfusion</i> , 2008 , 48, 1090-8	2.9	45
77	Quantitative assessment of the kinetics of growth factors release from platelet gel. <i>Transfusion</i> , 2008 , 48, 2414-20	2.9	72
76	Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems. <i>Haemophilia</i> , 2008 , 14, 956-62	3.3	22
75	Current strategies aimed at prevention of viral contamination of coagulation factor concentrates. <i>International Journal of Laboratory Hematology</i> , 2008 , 16, 398-399		
74	Cranioplasty using osteoconductive scaffold and platelet glue. <i>Journal of Trauma</i> , 2008 , 65, 1321-7		21
73	Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries. <i>ISBT Science Series</i> , 2007 , 2, 121-128	1.1	10
72	Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms. <i>Biologicals</i> , 2007 , 35, 329-34	1.8	16
71	Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma. <i>Biologicals</i> , 2007 , 35, 349-53	1.8	14
70	Modern plasma fractionation. <i>Transfusion Medicine Reviews</i> , 2007 , 21, 101-17	7.4	189
69	Biological and Biochemical Assays to Ensure the Quality and Safety of Plasma-Derived Products: Factor VIII Concentrates. <i>Current Pharmaceutical Analysis</i> , 2007 , 3, 83-94	0.6	3
68	Current strategies to prevent transmission of prions by human plasma derivatives. <i>Transfusion Clinique Et Biologique</i> , 2006 , 13, 320-8	1.9	35
67	Global Forum of the World Federation of Hemophilia, September 26-27, 2005, Montreal, Quebec, Canada. <i>Transfusion and Apheresis Science</i> , 2006 , 35, 151-172	2.4	1
66	A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system. <i>Vox Sanguinis</i> , 2006 , 91, 56-62	3.1	30

65	A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system. <i>Transfusion</i> , 2006 , 46, 2100-8	2.9	31
64	Place of Nanofiltration for Assuring Viral Safety of Biologicals. <i>Current Nanoscience</i> , 2005 , 1, 189-201	1.4	32
63	BLOOD-DERIVED, TISSUE ENGINEERING BIOMATERIALS. <i>Biomedical Engineering - Applications, Basis and Communications</i> , 2004 , 16, 294-304	0.6	1
62	Content and functional activity of von Willebrand factor in apheresis plasma. <i>Vox Sanguinis</i> , 2004 , 87, 27-33	3.1	9
61	Platelet-derived growth factor-AB and transforming growth factor-beta 1 in platelet gels activated by single-donor human thrombin. <i>Transfusion</i> , 2004 , 44, 945	2.9	24
60	Assessment of the viral safety of antivenoms fractionated from equine plasma. <i>Biologicals</i> , 2004 , 32, 115-28	1.8	58
59	Assessment of complement activation during membrane-based plasmapheresis procedures. <i>Journal of Clinical Apheresis</i> , 2004 , 19, 142-7	3.2	12
58	WHO Expert Committee on Biological Standardization. <i>Technical Report Series - World Health Organization, Geneva</i> , 2004 , 924, 1-232, backcover		17
57	Chromatographic purification and properties of a therapeutic human protein C concentrate. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 790, 199-207	3.2	6
56	Nanofiltration of single plasma donations: feasibility study. <i>Vox Sanguinis</i> , 2003 , 84, 111-9	3.1	30
55	Nanofiltration of plasma-derived biopharmaceutical products. <i>Haemophilia</i> , 2003 , 9, 24-37	3.3	159
54	Protein composition and activation markers in plasma collected by three apheresis procedures. <i>Transfusion</i> , 2003 , 43, 1223-30	2.9	18
53	Residual cell content in plasma produced by three centrifugal apheresis procedures. <i>Transfusion</i> , 2003 , 43, 1522-6	2.9	15
52	AIDS--past and future. <i>New England Journal of Medicine</i> , 2002 , 346, 710-1	59.2	1
51	Transmission of scrub typhus by blood transfusion?. <i>Transfusion</i> , 2001 , 41, 1454-5	2.9	2
50	Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2001 , 94, 599-607	2.7	18
49	Affinity chromatography in the industrial purification of plasma proteins for therapeutic use. <i>Journal of Proteomics</i> , 2001 , 49, 575-86		93
48	Purification of human ceruloplasmin as a by-product of C1-inhibitor. <i>Biological and Pharmaceutical Bulletin</i> , 2000 , 23, 1406-9	2.3	7

47	Virucidal heat-treatment of single plasma units: a potential approach for developing countries. <i>Haemophilia</i> , 2000 , 6, 597-604	3.3	14
46	Evaluation of a fibrin sealant free of bovine-derived components in an experimental vas anastomosis study. <i>Urologia Internationalis</i> , 2000 , 65, 196-9	1.9	8
45	Reducing the risk of infection from plasma products: specific preventative strategies. <i>Blood Reviews</i> , 2000 , 14, 94-110	11.1	154
44	Influence of formulation on jet nebulisation quality of alpha 1 protease inhibitor. <i>International Journal of Pharmaceutics</i> , 1999 , 178, 101-9	6.5	5
43	Application of bioaffinity technology in therapeutic extracorporeal plasmapheresis and large-scale fractionation of human plasma. <i>Biomedical Applications</i> , 1998 , 715, 65-80		21
42	Vasal reanastomosis using fibrin glue combined with sutures: which combination of sutures in a delayed protocol? Experimental study in rats. <i>European Urology</i> , 1998 , 33, 318-22	10.2	9
41	Delayed vasovasostomy: experimental study using fibrin glue. <i>European Urology</i> , 1997 , 31, 182-6	10.2	8
40	Fibrin Sealant: Scientific Rationale, Production Methods, Properties, and Current Clinical Use. <i>Vox Sanguinis</i> , 1997 , 72, 133-143	3.1	123
39	Jet nebulisation: Influence of dynamic conditions and nebuliser on nebulisation quality. Application to the α 1 protease inhibitor. <i>International Journal of Pharmaceutics</i> , 1997 , 148, 93-101	6.5	10
38	Evaluation of the effectiveness of different antifoams for an α 1 PI solution. <i>International Journal of Pharmaceutics</i> , 1997 , 156, 211-217	6.5	3
37	Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. <i>Vox Sanguinis</i> , 1997 , 72, 133-43	3.1	279
36	Development of an enzyme-linked immunosorbent assay for human plasma inter-alpha-trypsin inhibitor (ITI) using specific antibodies against each of the H1 and H2 heavy chains. <i>Journal of Immunological Methods</i> , 1996 , 190, 61-70	2.5	32
35	Value of virus filtration as a method for improving the safety of plasma products. <i>Vox Sanguinis</i> , 1996 , 70, 235-6	3.1	17
34	Delayed vasal reanastomosis in rats: comparison of a microsurgical technique and a fibrin-glued procedure. <i>British Journal of Urology</i> , 1996 , 78, 271-4		15
33	Chromatography in plasma fractionation: benefits and future trends. <i>Biomedical Applications</i> , 1995 , 664, 3-15		66
32	Albumin batches and B19 parvovirus DNA. <i>Transfusion</i> , 1995 , 35, 389-91	2.9	19
31	New trends in plasma fractionation and plasma products. <i>Vox Sanguinis</i> , 1994 , 67, 251-254	3.1	1
30	Nanofiltration, a New Specific Virus Elimination Method Applied to High-Purity Factor IX and Factor XI Concentrates. <i>Vox Sanguinis</i> , 1994 , 67, 132-138	3.1	6

29	Strategy of Virus Removal / Inactivation of Plasma-Derived Products : Interest of Nanofiltration as a New Virus Elimination Method 1994 , 17-27		3
28	Preparation and properties of a therapeutic inter-alpha-trypsin inhibitor concentrate from human plasma. <i>Vox Sanguinis</i> , 1994 , 67, 329-36	3.1	26
27	Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. <i>Vox Sanguinis</i> , 1994 , 67, 132-8	3.1	94
26	New trends in plasma fractionation and plasma products. <i>Vox Sanguinis</i> , 1994 , 67 Suppl 3, 251-3	3.1	6
25	Purification of factor VIII/von Willebrand factor from human plasma on immobilized lentil lectin. <i>Protein Expression and Purification</i> , 1994 , 5, 138-43	2	2
24	Chromatographic removal of viruses from plasma derivatives. <i>Developments in Biological Standardization</i> , 1993 , 81, 199-209		13
23	A pasteurized therapeutic plasma. <i>Transfusion Medicine and Hemotherapy</i> , 1992 , 19, 91-4	4.2	4
22	Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates. <i>Biologicals</i> , 1992 , 20, 91-100	1.8	28
21	A therapeutic, highly purified factor XI concentrate from human plasma. <i>Transfusion</i> , 1992 , 32, 861-7	2.9	32
20	Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. <i>Vox Sanguinis</i> , 1992 , 62, 1-11	3.1	51
19	A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. <i>Vox Sanguinis</i> , 1991 , 60, 8-15	3.1	64
18	A Highly Purified Factor VIII:c Concentrate Prepared from Cryoprecipitate by Ion-Exchange Chromatography. <i>Vox Sanguinis</i> , 1991 , 60, 8-15	3.1	1
17	Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 1991 , 45, 297-308	3.2	341
16	Comparison of High Purity Factor IX Concentrates and a Prothrombin Complex Concentrate in a Canine Model of Thrombogenicity. <i>Thrombosis and Haemostasis</i> , 1991 , 66, 609-613	7	12
15	Biochemical and physical properties of a solvent-detergent-treated fibrin glue. <i>Vox Sanguinis</i> , 1990 , 58, 77-84	3.1	43
14	Biochemical and Physical Properties of a Solvent-Detergent-Treated Fibrin Glue. <i>Vox Sanguinis</i> , 1990 , 58, 77-84	3.1	29
13	Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography. <i>Vox Sanguinis</i> , 1989 , 57, 225-32	3.1	64
12	Properties of a Highly Purified Human Plasma Factor IX:c Therapeutic Concentrate Prepared by Conventional Chromatography. <i>Vox Sanguinis</i> , 1989 , 57, 225-232	3.1	2

11	Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma. <i>Vox Sanguinis</i> , 1988 , 55, 202-10	3.1	33
10	Large-Scale Production and Properties of a Solvent-Detergent-Treated Factor IX Concentrate from Human Plasma. <i>Vox Sanguinis</i> , 1988 , 55, 202-210	3.1	24
9	Biochemical and biological properties of an alpha 1-antitrypsin concentrate. <i>Vox Sanguinis</i> , 1987 , 52, 291-7	3.1	31
8	Chromosomal control of wheat gliadin: analysis by reversed-phase high-performance liquid chromatography. <i>Theoretical and Applied Genetics</i> , 1985 , 70, 599-609	6	24
7	Chromosomal control of glutenin subunits in aneuploid lines of wheat: analysis by reversed-phase high-performance liquid chromatography. <i>Theoretical and Applied Genetics</i> , 1985 , 70, 610-9	6	26
6	Reversed-phase high-performance liquid chromatography of reduced glutenin, a disulfide-bonded protein of wheat endosperm. <i>Journal of Chromatography A</i> , 1984 , 299, 185-199	4.5	44
5	Reversed-phase high-performance liquid chromatography of durum wheat gliadins: Relationships to durum wheat quality. <i>Journal of Cereal Science</i> , 1984 , 2, 3-14	3.8	29
4	Inheritance of glutenin subunits in F1 seeds of reciprocal crosses between European hexaploid wheat cultivars. <i>Theoretical and Applied Genetics</i> , 1983 , 64, 103-7	6	15
3	Glutenin subunits of genetically related European hexaploid wheat cultivars: Their relation to bread-making quality. <i>Theoretical and Applied Genetics</i> , 1980 , 58, 107-11	6	65
2	Affinity Chromatography of Fractionated and DNA-Engineered Plasma Proteins ¹		
1	COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by explaining failures and finding signals of efficacy		4